| Status: Excluded due to NICE appraisal | |
Product meets AWMSG exclusion criteria due to NICE appraisal TA546: Padeliporfin for untreated localised prostate cancer |
|
Medicine details |
|
| Medicine name | padeliporfin (Tookad®) |
| Formulation | 183 mg and 366 mg powder for solution for injection |
| Reference number | 2940 |
| Indication | Monotherapy for adult patients with previously untreated, unilateral, low‑risk, adenocarcinoma of the prostate with a life expectancy ≥ 10 years and: Clinical stage T1c or T2a, Gleason Score ≤ 6, based on high-resolution biopsy strategies, PSA ≤ 10 ng/mL, 3 positive cancer cores with a maximum cancer core length of 5 mm in any one core or 1-2 positive cancer cores with ≥ 50% cancer involvement in any one core or a PSA density ≥ 0.15 ng/mL/cm3 |
| Company | STEBA Biotech |
| BNF chapter | Malignant disease & immunosuppression |
| Assessment type | N/A |
| Status | Excluded due to NICE appraisal |
| Date of issue | 02/11/2017 |
| NICE guidance | |